Is It Time to Offer Peanut Oral Immunotherapy to Toddlers?
Approximately 8% of children in the United States have any food allergy, and approximately 2% of all children are allergic to peanut.1 Peanut allergy accounts for the greatest number of fatalities due to food allergy.2 Food allergy is associated with diminished patient and parent health-related qual...
Gespeichert in:
Veröffentlicht in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2021-03, Vol.9 (3), p.1357-1358 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1358 |
---|---|
container_issue | 3 |
container_start_page | 1357 |
container_title | The journal of allergy and clinical immunology in practice (Cambridge, MA) |
container_volume | 9 |
creator | Burris, Amy D. Lomas, Jeanne M. Järvinen, Kirsi M. |
description | Approximately 8% of children in the United States have any food allergy, and approximately 2% of all children are allergic to peanut.1 Peanut allergy accounts for the greatest number of fatalities due to food allergy.2 Food allergy is associated with diminished patient and parent health-related quality of life including increased food anxiety, social limitations, and emotional distress.3 Lower eliciting doses for peanut are directly associated with lower health-related quality of life, likely due to the greater risk for reactions due to accidental ingestions.3 The current standard of care for treatment of peanut allergy at any age is to recommend strict dietary avoidance and educate patients and their families on how to treat an allergic reaction should an accidental exposure occur. Reaction histories were based on a graded scale from grade 1 (mild), grades 2 and 3 (moderate), and grades 4 and 5 (severe).6 Children had to have an objective history of reaction to peanut during an optional baseline oral food challenge (OFC) to a cumulative dose of |
doi_str_mv | 10.1016/j.jaip.2020.12.011 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2499385600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S221321982031343X</els_id><sourcerecordid>2499385600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-a74b24e715d195dfc586e009a45ac4aa64d872c415df8f3243e4267fd52683a53</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMoVmpfwIUMuHEzY25zE0GkeBko1EVdhzQ5gxnmZjIj9O3N0NaFC7M5Iec7PycfQlcERwST5K6KKmn6iGLqH2iECTlBF5QSFlKKyenxTvJshhbOVdifjKSY43M0YyzJ4oTQC3RfuKAYgo1pIBi6YF2WYIN3kO04BGsr66BomrHthk-wst9NyKbTugbrHi_RWSlrB4tDnaOPl-fN8i1crV-L5dMqVCzjQyhTvqUcUhJrkse6VHGWAMa55LFUXMqE6yylivt-mZWMcgacJmmpY5pkTMZsjm73ub3tvkZwg2iMU1DXsoVudILyPGf-Oxh79OYPWnWjbf12E5Vilsck9xTdU8p2zlkoRW9NI-1OECwmuaISk1wxyRWECi_XD10fosdtA_p35KjSAw97ALyLbwNWOGWgVaCNBTUI3Zn_8n8AtUCHHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2497039519</pqid></control><display><type>article</type><title>Is It Time to Offer Peanut Oral Immunotherapy to Toddlers?</title><source>Alma/SFX Local Collection</source><creator>Burris, Amy D. ; Lomas, Jeanne M. ; Järvinen, Kirsi M.</creator><creatorcontrib>Burris, Amy D. ; Lomas, Jeanne M. ; Järvinen, Kirsi M.</creatorcontrib><description>Approximately 8% of children in the United States have any food allergy, and approximately 2% of all children are allergic to peanut.1 Peanut allergy accounts for the greatest number of fatalities due to food allergy.2 Food allergy is associated with diminished patient and parent health-related quality of life including increased food anxiety, social limitations, and emotional distress.3 Lower eliciting doses for peanut are directly associated with lower health-related quality of life, likely due to the greater risk for reactions due to accidental ingestions.3 The current standard of care for treatment of peanut allergy at any age is to recommend strict dietary avoidance and educate patients and their families on how to treat an allergic reaction should an accidental exposure occur. Reaction histories were based on a graded scale from grade 1 (mild), grades 2 and 3 (moderate), and grades 4 and 5 (severe).6 Children had to have an objective history of reaction to peanut during an optional baseline oral food challenge (OFC) to a cumulative dose of <300 mg of peanut protein and evidence of sensitization. There were also more adverse events in POIT among older children with 87.1% of participants experiencing an adverse event in the 4- to 17-year age group9 compared with the 10.5% of preschool children who had reactions during maintenance in this study on the same 300 mg maintenance dose.5 A strength of this study is the applicability to the real-world setting as POIT was performed in community allergy clinics for almost 90% of the patients.</description><identifier>ISSN: 2213-2198</identifier><identifier>EISSN: 2213-2201</identifier><identifier>DOI: 10.1016/j.jaip.2020.12.011</identifier><identifier>PMID: 33685612</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age groups ; Children ; Food allergies ; Immunotherapy ; Preschool children ; Proteins ; Quality of life</subject><ispartof>The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-03, Vol.9 (3), p.1357-1358</ispartof><rights>2020 American Academy of Allergy, Asthma & Immunology</rights><rights>2020. American Academy of Allergy, Asthma & Immunology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-a74b24e715d195dfc586e009a45ac4aa64d872c415df8f3243e4267fd52683a53</citedby><cites>FETCH-LOGICAL-c384t-a74b24e715d195dfc586e009a45ac4aa64d872c415df8f3243e4267fd52683a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33685612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burris, Amy D.</creatorcontrib><creatorcontrib>Lomas, Jeanne M.</creatorcontrib><creatorcontrib>Järvinen, Kirsi M.</creatorcontrib><title>Is It Time to Offer Peanut Oral Immunotherapy to Toddlers?</title><title>The journal of allergy and clinical immunology in practice (Cambridge, MA)</title><addtitle>J Allergy Clin Immunol Pract</addtitle><description>Approximately 8% of children in the United States have any food allergy, and approximately 2% of all children are allergic to peanut.1 Peanut allergy accounts for the greatest number of fatalities due to food allergy.2 Food allergy is associated with diminished patient and parent health-related quality of life including increased food anxiety, social limitations, and emotional distress.3 Lower eliciting doses for peanut are directly associated with lower health-related quality of life, likely due to the greater risk for reactions due to accidental ingestions.3 The current standard of care for treatment of peanut allergy at any age is to recommend strict dietary avoidance and educate patients and their families on how to treat an allergic reaction should an accidental exposure occur. Reaction histories were based on a graded scale from grade 1 (mild), grades 2 and 3 (moderate), and grades 4 and 5 (severe).6 Children had to have an objective history of reaction to peanut during an optional baseline oral food challenge (OFC) to a cumulative dose of <300 mg of peanut protein and evidence of sensitization. There were also more adverse events in POIT among older children with 87.1% of participants experiencing an adverse event in the 4- to 17-year age group9 compared with the 10.5% of preschool children who had reactions during maintenance in this study on the same 300 mg maintenance dose.5 A strength of this study is the applicability to the real-world setting as POIT was performed in community allergy clinics for almost 90% of the patients.</description><subject>Age groups</subject><subject>Children</subject><subject>Food allergies</subject><subject>Immunotherapy</subject><subject>Preschool children</subject><subject>Proteins</subject><subject>Quality of life</subject><issn>2213-2198</issn><issn>2213-2201</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEUhoMoVmpfwIUMuHEzY25zE0GkeBko1EVdhzQ5gxnmZjIj9O3N0NaFC7M5Iec7PycfQlcERwST5K6KKmn6iGLqH2iECTlBF5QSFlKKyenxTvJshhbOVdifjKSY43M0YyzJ4oTQC3RfuKAYgo1pIBi6YF2WYIN3kO04BGsr66BomrHthk-wst9NyKbTugbrHi_RWSlrB4tDnaOPl-fN8i1crV-L5dMqVCzjQyhTvqUcUhJrkse6VHGWAMa55LFUXMqE6yylivt-mZWMcgacJmmpY5pkTMZsjm73ub3tvkZwg2iMU1DXsoVudILyPGf-Oxh79OYPWnWjbf12E5Vilsck9xTdU8p2zlkoRW9NI-1OECwmuaISk1wxyRWECi_XD10fosdtA_p35KjSAw97ALyLbwNWOGWgVaCNBTUI3Zn_8n8AtUCHHA</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Burris, Amy D.</creator><creator>Lomas, Jeanne M.</creator><creator>Järvinen, Kirsi M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>202103</creationdate><title>Is It Time to Offer Peanut Oral Immunotherapy to Toddlers?</title><author>Burris, Amy D. ; Lomas, Jeanne M. ; Järvinen, Kirsi M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-a74b24e715d195dfc586e009a45ac4aa64d872c415df8f3243e4267fd52683a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age groups</topic><topic>Children</topic><topic>Food allergies</topic><topic>Immunotherapy</topic><topic>Preschool children</topic><topic>Proteins</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burris, Amy D.</creatorcontrib><creatorcontrib>Lomas, Jeanne M.</creatorcontrib><creatorcontrib>Järvinen, Kirsi M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burris, Amy D.</au><au>Lomas, Jeanne M.</au><au>Järvinen, Kirsi M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is It Time to Offer Peanut Oral Immunotherapy to Toddlers?</atitle><jtitle>The journal of allergy and clinical immunology in practice (Cambridge, MA)</jtitle><addtitle>J Allergy Clin Immunol Pract</addtitle><date>2021-03</date><risdate>2021</risdate><volume>9</volume><issue>3</issue><spage>1357</spage><epage>1358</epage><pages>1357-1358</pages><issn>2213-2198</issn><eissn>2213-2201</eissn><abstract>Approximately 8% of children in the United States have any food allergy, and approximately 2% of all children are allergic to peanut.1 Peanut allergy accounts for the greatest number of fatalities due to food allergy.2 Food allergy is associated with diminished patient and parent health-related quality of life including increased food anxiety, social limitations, and emotional distress.3 Lower eliciting doses for peanut are directly associated with lower health-related quality of life, likely due to the greater risk for reactions due to accidental ingestions.3 The current standard of care for treatment of peanut allergy at any age is to recommend strict dietary avoidance and educate patients and their families on how to treat an allergic reaction should an accidental exposure occur. Reaction histories were based on a graded scale from grade 1 (mild), grades 2 and 3 (moderate), and grades 4 and 5 (severe).6 Children had to have an objective history of reaction to peanut during an optional baseline oral food challenge (OFC) to a cumulative dose of <300 mg of peanut protein and evidence of sensitization. There were also more adverse events in POIT among older children with 87.1% of participants experiencing an adverse event in the 4- to 17-year age group9 compared with the 10.5% of preschool children who had reactions during maintenance in this study on the same 300 mg maintenance dose.5 A strength of this study is the applicability to the real-world setting as POIT was performed in community allergy clinics for almost 90% of the patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33685612</pmid><doi>10.1016/j.jaip.2020.12.011</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2213-2198 |
ispartof | The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-03, Vol.9 (3), p.1357-1358 |
issn | 2213-2198 2213-2201 |
language | eng |
recordid | cdi_proquest_miscellaneous_2499385600 |
source | Alma/SFX Local Collection |
subjects | Age groups Children Food allergies Immunotherapy Preschool children Proteins Quality of life |
title | Is It Time to Offer Peanut Oral Immunotherapy to Toddlers? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A23%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20It%20Time%20to%20Offer%20Peanut%20Oral%20Immunotherapy%20to%20Toddlers?&rft.jtitle=The%20journal%20of%20allergy%20and%20clinical%20immunology%20in%20practice%20(Cambridge,%20MA)&rft.au=Burris,%20Amy%20D.&rft.date=2021-03&rft.volume=9&rft.issue=3&rft.spage=1357&rft.epage=1358&rft.pages=1357-1358&rft.issn=2213-2198&rft.eissn=2213-2201&rft_id=info:doi/10.1016/j.jaip.2020.12.011&rft_dat=%3Cproquest_cross%3E2499385600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2497039519&rft_id=info:pmid/33685612&rft_els_id=S221321982031343X&rfr_iscdi=true |